Astellas Pharma Inc (ALPMF) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you very much for your joining with us. This is the FY25, the third quarter earnings goal. My name is Kato. I'm serving as the moderator for today. I am chief communications and IR officer. Today, following our presentation, we will proceed to the Q&A session. The presentation will follow the presentation materials available on our website. The session, including Q&A, will be conducted with simultaneous interpretation in Japanese and English, please note that we cannot guarantee the accuracy of the simultaneous interpretation. You may select your language from the menu on the Zoom webinar screen. If you choose the original language, you can view the presentation in the original audio without simultaneous interpretation. This is some notes for today's presentation. This material presentation and answers and statement by representatives for the company in the QA session includes forward-looking statements based on assumptions, benefits, or beliefs, rather, in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially, depending on a number of factors. They contain information of pharmaceuticals, including compounds under development, but this information does not intend to make any representations or advertisements regarding the efficacy or effectiveness of these preparations. Promote unapproved uses in any fashion or provide medical advice of any kind. The participants for here today is Asushi Kitamura, CFO, Chief Financial Officer. Tadaki Taniguchi, CRO, Chief Research and Development Officer. Klaus Seuler, Chief Commercial and Medical Affairs, CCMAO. We have three of them with us here today. We start the presentation now. Kitamura-san, the floor is yours. Hello, ...